Literature DB >> 12225998

Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20-44 years of age.

Julie A Britton1, Marilie D Gammon, Janet B Schoenberg, Janet L Stanford, Ralph J Coates, Christine A Swanson, Nancy Potischman, Kathleen E Malone, Donna J Brogan, Janet R Daling, Louise A Brinton.   

Abstract

To gain insight into whether breast cancer tumors jointly classified by estrogen receptor (ER) and progesterone receptor (PR) status represent diseases with differing etiologies, data from a population-based case-control study of US women 20-44 years of age were analyzed. Cases included 1,556 women diagnosed between 1990 and 1992. Age- and geographic-frequency-matched controls included 1,397 women identified by random digit dialing. Heterogeneity between ER+PR+ and ER-PR- tumors was most pronounced in relation to age, race, and recreational exercise at 12-13 years of age. Multivariate-adjusted odds ratios for ER+PR+ tumors were 0.64 (95% confidence interval (CI): 0.47, 0.89) for 30-34 versus 40-44 years of age, 0.89 (95% CI: 0.63, 1.25) for Black versus White race, and 0.84 (95% CI: 0.68, 1.03) for exercise at 12-13 years of age above versus at or below the median. Corresponding odds ratios for ER-PR- tumors were 1.24 (95% CI: 0.86, 1.77), 1.51 (95% CI: 1.07, 2.14), and 1.15 (95% CI: 0.90, 1.48). Risk of ER-PR- cancer in relation to menstrual and reproductive (parity and lactation) characteristics, alcohol consumption, and family history of breast cancer was similar to that observed for ER+PR+ tumors. These findings only modestly support the hypothesis that hormonally related risk factors have differing relations with ER+PR+ versus ER-PR- tumors among younger women.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12225998     DOI: 10.1093/aje/kwf065

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  30 in total

1.  A method for the assessment of disease associations with single-nucleotide polymorphism haplotypes and environmental variables in case-control studies.

Authors:  Lue Ping Zhao; Shuying Sue Li; Najma Khalid
Journal:  Am J Hum Genet       Date:  2003-04-16       Impact factor: 11.025

2.  Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer.

Authors:  Walter Schippinger; Peter Regitnig; Nadia Dandachi; Klaus-Dieter Wernecke; Thomas Bauernhofer; Hellmut Samonigg; Farid Moinfar
Journal:  Virchows Arch       Date:  2006-04-21       Impact factor: 4.064

3.  FGFR2 gene polymorphisms are associated with breast cancer risk in the Han Chinese population.

Authors:  Peng Xia; Bin Li; Tingting Geng; Zhiping Deng; Chengxue Dang; Dongmin Chang; Longli Kang; Tianbo Jin; Chao Chen
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

4.  Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years.

Authors:  Masaaki Kawai; Kathleen E Malone; Mei-Tzu C Tang; Christopher I Li
Journal:  Cancer       Date:  2014-02-05       Impact factor: 6.860

5.  Association of physical activity with hormone receptor status: the Shanghai Breast Cancer Study.

Authors:  Swann Arp Adams; Charles E Matthews; James R Hebert; Charity G Moore; Joan E Cunningham; Xiou-Oi Shu; Jeanette Fulton; Yutang Gao; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-06       Impact factor: 4.254

6.  Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study.

Authors:  Ping-Ping Bao; Xiao Ou Shu; Yu-Tang Gao; Ying Zheng; Hui Cai; Sandra L Deming; Zhi-Xian Ruan; Yinghao Su; Kai Gu; Wei Lu; Wei Zheng
Journal:  Am J Epidemiol       Date:  2011-07-18       Impact factor: 4.897

7.  Differential Patterns of Risk Factors for Early-Onset Breast Cancer by ER Status in African American Women.

Authors:  Kimberly A Bertrand; Traci N Bethea; Lucile L Adams-Campbell; Lynn Rosenberg; Julie R Palmer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-10-18       Impact factor: 4.254

8.  Total energy intake and breast cancer risk in sisters: the Breast Cancer Family Registry.

Authors:  Fang Fang Zhang; Esther M John; Julia A Knight; Manleen Kaur; Mary Daly; Saundra Buys; Irene L Andrulis; Beth Stearman; Dee West; Mary Beth Terry
Journal:  Breast Cancer Res Treat       Date:  2012-12-06       Impact factor: 4.872

9.  Incorporating tumour pathology information into breast cancer risk prediction algorithms.

Authors:  Nasim Mavaddat; Timothy R Rebbeck; Sunil R Lakhani; Douglas F Easton; Antonis C Antoniou
Journal:  Breast Cancer Res       Date:  2010-05-18       Impact factor: 6.466

10.  Polychlorinated biphenyls and breast cancer risk by combined estrogen and progesterone receptor status.

Authors:  Jennifer A Rusiecki; Theodore R Holford; Shelia H Zahm; Tonzhang Zheng
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.